{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:59:20Z","timestamp":1792015160684,"version":"4.4.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"Abstract<\/jats:title>\n Purpose<\/jats:title>\n Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver disease, affecting 30% of the global population. NAFLD prevalence is particularly high in obese individuals and patients with type 2 diabetes mellitus (T2DM). NAFLD ranges from simple fat deposition in the liver to necroinflammation and fibrosis (non-alcoholic steatohepatitis (NASH)), NASH-cirrhosis, and\/or hepatocellular carcinoma. Insulin resistance plays a key role in NAFLD pathogenesis, alongside dysregulation of adipocytes, mitochondrial dysfunction, genetic factors, and changes in gut microbiota. Since insulin resistance is also a major predisposing factor of T2DM, the administration of anti-diabetic drugs for the management of NAFLD seems reasonable.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n In this review we provide the NAFLD-associated mechanisms of action of some of the most widely used anti-diabetic drugs, namely metformin, pioglitazone, sodium-glucose transport protein-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor analogs (GLP1 RAs), and dipeptyl-peptidase-4 inhibitors (DPP4i) and present available data regarding their use in patients with NAFLD, with and without T2DM.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n Both metformin and DPP4i have shown rather contradictory results, while pioglitazone seems to benefit patients with NASH and is thus the only drug approved for NASH with concomitant significant liver fibrosis by all major liver societies. On the other hand, SGLT2i and GLP1 RAs seem to be beneficiary in patients with NAFLD, showing both remarkable results, with SGLT2i proving to be more efficient in the only head-to-head study so far.<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n In patients with NAFLD and diabetes, pioglitazone, GLP1 RAs, and SGLT2i seem to be logical treatment options. Larger studies are needed before these drugs can be recommended for non-diabetic individuals.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00228-023-03586-1","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T14:02:26Z","timestamp":1699452146000},"page":"127-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5156-9553","authenticated-orcid":false,"given":"Maria","family":"Zachou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-7944","authenticated-orcid":false,"given":"Pagona","family":"Flevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-693X","authenticated-orcid":false,"given":"Narjes","family":"Nasiri-Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-685X","authenticated-orcid":false,"given":"Constantinos","family":"Varytimiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-8914","authenticated-orcid":false,"given":"Evangelos","family":"Kalaitzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-2297","authenticated-orcid":false,"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-6230","authenticated-orcid":false,"given":"Theodoros","family":"Androutsakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"3586_CR1","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology\u00a077(4):1335\u20131347.\u00a0https:\/\/doi.org\/10.1097\/HEP.0000000000000004. Epub 2023 Jan 3. PMID: 36626630; PMCID: PMC10026948","DOI":"10.1097\/HEP.0000000000000004"},{"key":"3586_CR2","doi-asserted-by":"publisher","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH (2019) Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol\u00a0389\u2013398. https:\/\/doi.org\/10.1016\/S2468-1253(19)30039-1.\u00a0PMID: 30902670","DOI":"10.1016\/S2468-1253(19)30039-1"},{"key":"3586_CR3","doi-asserted-by":"publisher","unstructured":"Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J (2003) Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38:420\u20137. https:\/\/doi.org\/10.1053\/jhep.2003.50320.\u00a0PMID: 12883486","DOI":"10.1053\/jhep.2003.50320"},{"key":"3586_CR4","doi-asserted-by":"publisher","unstructured":"Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134\u201340. https:\/\/doi.org\/10.1053\/gast.2002.34168.\u00a0PMID: 12105842","DOI":"10.1053\/gast.2002.34168"},{"key":"3586_CR5","doi-asserted-by":"publisher","unstructured":"Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M (2017) Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole feature of liver damage. PLoS one 12:e0178473. https:\/\/doi.org\/10.1371\/journal.pone.0178473.\u00a0PMID: 28570615; PMCID: PMC5453539","DOI":"10.1371\/journal.pone.0178473"},{"key":"3586_CR6","doi-asserted-by":"publisher","unstructured":"Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC (2021) Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants (basel) 10:270.\u00a0https:\/\/doi.org\/10.3390\/antiox10020270.\u00a0PMID: 33578702; PMCID: PMC7916383","DOI":"10.3390\/antiox10020270"},{"key":"3586_CR7","doi-asserted-by":"publisher","unstructured":"Fargion S, Porzio M, Fracanzani AL (2014) Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 20:13306\u201324. https:\/\/doi.org\/10.3748\/wjg.v20.i37.13306.\u00a0PMID: 25309067; PMCID: PMC4188888","DOI":"10.3748\/wjg.v20.i37.13306"},{"key":"3586_CR8","doi-asserted-by":"publisher","unstructured":"Tarantino G, Crocetto F, Di Vito C, Creta M, Martino R, Pandolfo SD, Pesce S, Napolitano L, Capone D, Imbimbo C (2021) Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study. J Clin Med 10(2):346. https:\/\/doi.org\/10.3390\/jcm10020346.\u00a0PMID: 33477579; PMCID: PMC7831331","DOI":"10.3390\/jcm10020346"},{"key":"3586_CR9","doi-asserted-by":"publisher","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G (2022) Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 71(4):778\u2013788. https:\/\/doi.org\/10.1136\/gutjnl-2021-324191.\u00a0PMID: 33685968","DOI":"10.1136\/gutjnl-2021-324191"},{"key":"3586_CR10","doi-asserted-by":"publisher","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u201348. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.\u00a0PMID: 26823198","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"3586_CR11","doi-asserted-by":"publisher","unstructured":"Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68:268\u2013279. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003.\u00a0PMID: 29122391","DOI":"10.1016\/j.jhep.2017.09.003"},{"key":"3586_CR12","doi-asserted-by":"publisher","unstructured":"Marra F, Bertolani C (2009) Adipokines in liver diseases. Hepatology 50(3):957\u201369. https:\/\/doi.org\/10.1002\/hep.23046.\u00a0PMID: 19585655","DOI":"10.1002\/hep.23046"},{"key":"3586_CR13","doi-asserted-by":"publisher","unstructured":"Mahady SE, George J (2016) Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism\u00a065:1172\u201382. https:\/\/doi.org\/10.1016\/j.metabol.2015.10.032.\u00a0PMID: 26805014","DOI":"10.1016\/j.metabol.2015.10.032"},{"key":"3586_CR14","doi-asserted-by":"publisher","unstructured":"Perry RJ, Samuel VT, Petersen KF, Shulman GI (2014) The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510(7503):84\u201391. https:\/\/doi.org\/10.1038\/nature13478.\u00a0PMID: 24899308; PMCID: PMC4489847","DOI":"10.1038\/nature13478"},{"key":"3586_CR15","doi-asserted-by":"publisher","unstructured":"Marra F, Svegliati-Baroni G (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol\u00a068:280\u2013295. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.014.\u00a0PMID: 29154964","DOI":"10.1016\/j.jhep.2017.11.014"},{"key":"3586_CR16","doi-asserted-by":"publisher","unstructured":"Mansouri A, Gattolliat CH, Asselah T (2018) Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 155:629\u2013647. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.083.\u00a0PMID: 30012333","DOI":"10.1053\/j.gastro.2018.06.083"},{"key":"3586_CR17","doi-asserted-by":"publisher","unstructured":"Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros CS, Kyriakopoulos G, Chatzigeorgiou A, Kalotychou V, Randeva MS, Chatha K, Kontzoglou K, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E (2021) Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-\/-) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci 22:818. https:\/\/doi.org\/10.3390\/ijms22020818.\u00a0PMID: 33467546; PMCID: PMC7829901","DOI":"10.3390\/ijms22020818"},{"key":"3586_CR18","doi-asserted-by":"publisher","unstructured":"Xiong X, Wang X, Lu Y, Wang E, Zhang Z, Yang J, Zhang H, Li X (2014) Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 60:847\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.003.\u00a0PMID: 24333182","DOI":"10.1016\/j.jhep.2013.12.003"},{"key":"3586_CR19","doi-asserted-by":"publisher","unstructured":"Zhang X, Han J, Man K, Li X, Du J, Chu ES, Go MY, Sung JJ, Yu J (2016) CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol 64(1):160\u201370. https:\/\/doi.org\/10.1016\/j.jhep.2015.09.005.\u00a0PMID: 26394162","DOI":"10.1016\/j.jhep.2015.09.005"},{"key":"3586_CR20","doi-asserted-by":"publisher","unstructured":"Alkhouri N, Carter-Kent C, Feldstein AE (2011) Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.\u00a0Expert Rev Gastroenterol Hepatol\u00a05(2):201\u201312. https:\/\/doi.org\/10.1586\/egh.11.6.\u00a0PMID: 21476915; PMCID: PMC3119461","DOI":"10.1586\/egh.11.6"},{"key":"3586_CR21","doi-asserted-by":"publisher","unstructured":"Cai J, Zhang XJ, Li H (2019) The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology\u00a070(3):1026\u20131037. https:\/\/doi.org\/10.1002\/hep.30506.\u00a0PMID: 30653691","DOI":"10.1002\/hep.30506"},{"key":"3586_CR22","doi-asserted-by":"publisher","unstructured":"Lee YA, Friedman SL (2022) Inflammatory and fibrotic mechanisms in NAFLD-implications for new treatment strategies. J Intern Med 291:11\u201331. https:\/\/doi.org\/10.1111\/joim.13380.\u00a0PMID: 34564899; PMCID: PMC8688191","DOI":"10.1111\/joim.13380"},{"key":"3586_CR23","doi-asserted-by":"publisher","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343\u201351. https:\/\/doi.org\/10.1172\/JCI23621.\u00a0PMID: 15864352; PMCID: PMC1087172","DOI":"10.1172\/JCI23621"},{"key":"3586_CR24","doi-asserted-by":"publisher","unstructured":"Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, Jones GM, Palii SP, Velasco-Alin M, Pan K, Patterson BW, Gugliucci A, Lustig RH, Mulligan K (2017) Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 153:743\u2013752.\u00a0https:\/\/doi.org\/10.1053\/j.gastro.2017.05.043.\u00a0PMID: 28579536; PMCID: PMC5813289","DOI":"10.1053\/j.gastro.2017.05.043"},{"key":"3586_CR25","doi-asserted-by":"publisher","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E (2022) SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci 23(6):3107. https:\/\/doi.org\/10.3390\/ijms23063107.\u00a0PMID: 35328527; PMCID: PMC8953901","DOI":"10.3390\/ijms23063107"},{"key":"3586_CR26","doi-asserted-by":"publisher","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367\u201378.e5; quiz e14\u20135. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.\u00a0PMID: 25865049","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"3586_CR27","doi-asserted-by":"publisher","unstructured":"Petroni ML, Brodosi L, Bugianesi E, Marchesini G (2021) Management of non-alcoholic fatty liver disease. BMJ 372:m4747. https:\/\/doi.org\/10.1136\/bmj.m4747.\u00a0PMID: 33461969","DOI":"10.1136\/bmj.m4747"},{"key":"3586_CR28","doi-asserted-by":"publisher","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367.\u00a0PMID: 28714183","DOI":"10.1002\/hep.29367"},{"key":"3586_CR29","doi-asserted-by":"publisher","unstructured":"Tarantino G, Balsano C, Santini SJ, Brienza G, Clemente I, Cosimini B, Sinatti G (2021) It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them? Int J Mol Sci\u00a022(24):13424. https:\/\/doi.org\/10.3390\/ijms222413424.\u00a0PMID: 34948230; PMCID: PMC8706322","DOI":"10.3390\/ijms222413424"},{"issue":"24","key":"3586_CR30","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","volume":"23","author":"X Guo","year":"2022","unstructured":"Guo X, Yin X, Liu Z, Wang J (2022) Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci 23(24):15489. https:\/\/doi.org\/10.3390\/ijms232415489. PMID: 36555127; PMCID: PMC9779435","journal-title":"Int J Mol Sci"},{"key":"3586_CR31","doi-asserted-by":"publisher","unstructured":"Flory J, Lipska K (2019) Metformin in 2019. JAMA 321(19):1926\u20131927. https:\/\/doi.org\/10.1001\/jama.2019.3805.\u00a0PMID: 31009043; PMCID: PMC7552083","DOI":"10.1001\/jama.2019.3805"},{"key":"3586_CR32","unstructured":"FDA.\u00a0Label information: glucophage tablets and glucophage XR extended-release tablets. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020357s037s039,021202s021s023lbl.pdf.\u00a0Accessed 21 Jul 2022"},{"key":"3586_CR33","doi-asserted-by":"publisher","unstructured":"American Diabetes Association (2019) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes care 42:S90-S102. https:\/\/doi.org\/10.2337\/dc19-S009.\u00a0PMID: 30559235","DOI":"10.2337\/dc19-S009"},{"key":"3586_CR34","doi-asserted-by":"publisher","unstructured":"Nardo LG, Rai R (2001) Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol endocrinol\u00a0 15(5):373\u201380. https:\/\/doi.org\/10.1080\/gye.15.5.373.380.\u00a0PMID: 11727360","DOI":"10.1080\/gye.15.5.373.380"},{"key":"3586_CR35","doi-asserted-by":"publisher","unstructured":"Lee JW, Choi EA, Kim YS, Kim Y, You HS, Han YE, Kim HS, Bae YJ, Kim J, Kang HT (2021) Metformin usage and the risk of colorectal cancer: a national cohort study. Int J Colorectal Dis 36(2):303\u2013310. https:\/\/doi.org\/10.1007\/s00384-020-03765-x.\u00a0PMID: 32968891","DOI":"10.1007\/s00384-020-03765-x"},{"key":"3586_CR36","doi-asserted-by":"publisher","unstructured":"Cunha J\u00fanior AD, Bragagnoli AC, Costa FO, Carvalheira JBC (2021) Repurposing metformin for the treatment of gastrointestinal cancer. World J Gastroenterol\u00a027(17):1883\u20131904. https:\/\/doi.org\/10.3748\/wjg.v27.i17.1883.\u00a0PMID: 34007128; PMCID: PMC8108031","DOI":"10.3748\/wjg.v27.i17.1883"},{"key":"3586_CR37","doi-asserted-by":"publisher","unstructured":"Luo CS, Lin Y, Zhou WP, Shi J (2020) Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. Eur J Gastroenterol Hepatol\u00a032(8):1030\u20131035. https:\/\/doi.org\/10.1097\/MEG.0000000000001610.\u00a0PMID: 31764404; PMCID: PMC7337117","DOI":"10.1097\/MEG.0000000000001610"},{"key":"3586_CR38","doi-asserted-by":"publisher","unstructured":"Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N (2021) Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut liver 15(6):827\u2013840. https:\/\/doi.org\/10.5009\/gnl20367.\u00a0PMID: 33820884; PMCID: PMC8593497","DOI":"10.5009\/gnl20367"},{"key":"3586_CR39","doi-asserted-by":"publisher","unstructured":"Petersen MC, Vatner DF, Shulman GI (2017) Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol 13:572\u2013587. https:\/\/doi.org\/10.1038\/nrendo.2017.80.\u00a0PMID: 28731034; PMCID: PMC5777172","DOI":"10.1038\/nrendo.2017.80"},{"key":"3586_CR40","doi-asserted-by":"publisher","unstructured":"Song YM, Lee YH, Kim JW, Ham DS, Kang ES, Cha BS, Lee HC, Lee BW (2015) Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy 11:46\u201359. https:\/\/doi.org\/10.4161\/15548627.2014.984271.\u00a0PMID: 25484077; PMCID: PMC4502778","DOI":"10.4161\/15548627.2014.984271"},{"key":"3586_CR41","doi-asserted-by":"publisher","unstructured":"Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O'Neill HM, Ford RJ, Palanivel R, O'Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE, Steinberg GR (2013) Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat med\u00a019:1649\u201354. https:\/\/doi.org\/10.1038\/nm.3372.\u00a0PMID: 24185692; PMCID: PMC4965268","DOI":"10.1038\/nm.3372"},{"key":"3586_CR42","doi-asserted-by":"publisher","unstructured":"Huang H, Lee SH, Sousa-Lima I, Kim SS, Hwang WM, Dagon Y, Yang WM, Cho S, Kang MC, Seo JA, Shibata M, Cho H, Belew GD, Bhin J, Desai BN, Ryu MJ, Shong M, Li P, Meng H, Chung BH, Hwang D, Kim MS, Park KS, Macedo MP, White M, Jones J, Kim YB (2018) Rho-kinase\/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest 128(12):5335\u20135350. https:\/\/doi.org\/10.1172\/JCI63562.\u00a0PMID: 30226474; PMCID: PMC6264719","DOI":"10.1172\/JCI63562"},{"key":"3586_CR43","doi-asserted-by":"publisher","unstructured":"Ford RJ, Fullerton MD, Pinkosky SL, Day EA, Scott JW, Oakhill JS, Bujak AL, Smith BK, Crane JD, Bl\u00fcmer RM, Marcinko K, Kemp BE, Gerstein HC, Steinberg GR (2015) Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J\u00a0468(1):125\u201332. https:\/\/doi.org\/10.1042\/BJ20150125.\u00a0PMID: 25742316 PMCID: PMC5233440","DOI":"10.1042\/BJ20150125"},{"key":"3586_CR44","doi-asserted-by":"publisher","unstructured":"Yan C, Tian X, Li J, Liu D, Ye D, Xie Z, Han Y, Zou MH (2021) A high-fat diet attenuates AMPK \u03b11 in adipocytes to induce exosome shedding and nonalcoholic fatty liver development in vivo. Diabetes\u00a070(2):577\u2013588. https:\/\/doi.org\/10.2337\/db20-0146.\u00a0PMID: 33262120; PMCID: PMC7881856","DOI":"10.2337\/db20-0146"},{"key":"3586_CR45","doi-asserted-by":"publisher","unstructured":"de Jes\u00fas Acosta-Cota S, Aguilar-Medina EM, Ramos-Pay\u00e1n R, Rend\u00f3n Maldonado JG, Romero-Quintana JG, Montes-Avila J, Sarmiento-S\u00e1nchez JI, Plazas-Guerrero CG, Vergara-Jim\u00e9nez MJ, S\u00e1nchez-L\u00f3pez A, Centuri\u00f3n D, Osuna-Mart\u00ednez U (2019) Therapeutic effect of treatment with metformin and\/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. Eur J Pharmacol 863:172699. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172699.\u00a0PMID: 31563650","DOI":"10.1016\/j.ejphar.2019.172699"},{"key":"3586_CR46","doi-asserted-by":"publisher","unstructured":"Stachowicz A, Suski M, Olszanecki R, Madej J, Oko\u0144 K, Korbut R (2012) Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin. J Proteomics 77:167\u20137. https:\/\/doi.org\/10.1016\/j.jprot.2012.08.015.\u00a0PMID: 22960565","DOI":"10.1016\/j.jprot.2012.08.015"},{"key":"3586_CR47","doi-asserted-by":"publisher","unstructured":"Mahzari A, Li S, Zhou X, Li D, Fouda S, Alhomrani M, Alzahrani W, Robinson SR, Ye JM (2019) Matrine protects against MCD-induced development of NASH via upregulating HSP72 and downregulating mTOR in a manner distinctive from metformin. Front Pharmacol 10:405. https:\/\/doi.org\/10.3389\/fphar.2019.00405.\u00a0PMID: 31068812; PMCID: PMC6491841","DOI":"10.3389\/fphar.2019.00405"},{"key":"3586_CR48","doi-asserted-by":"publisher","unstructured":"Matafome P, Louro T, Rodrigues L, Cris\u00f3stomo J, Nunes E, Amaral C, Monteiro P, Cipriano A, Sei\u00e7a R (2011) Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 27(1):54\u201362. https:\/\/doi.org\/10.1002\/dmrr.1157.\u00a0PMID: 21218508","DOI":"10.1002\/dmrr.1157"},{"key":"3586_CR49","doi-asserted-by":"publisher","unstructured":"Brandt A, Hern\u00e1ndez-Arriaga A, Kehm R, S\u00e1nchez V, Jin CJ, Nier A, Baumann A, Camarinha-Silva A, Bergheim I (2019) Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. Sci Rep 9(1):6668. https:\/\/doi.org\/10.1038\/s41598-019-43228-0.\u00a0PMID: 31040374; PMCID: PMC6491483","DOI":"10.1038\/s41598-019-43228-0"},{"key":"3586_CR50","doi-asserted-by":"publisher","unstructured":"Shin NR, Bose S, Wang JH, Ansari A, Lim SK, Chin YW, Choi HS, Kim H (2017)\u00a0Flos Lonicera combined with metformin ameliorates hepatosteatosis and glucose intolerance in association with gut microbiota modulation. Front Microbiol 8:2271. https:\/\/doi.org\/10.3389\/fmicb.2017.02271.\u00a0PMID: 29204141; PMCID: PMC5698303","DOI":"10.3389\/fmicb.2017.02271"},{"key":"3586_CR51","doi-asserted-by":"publisher","unstructured":"Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Gao LJ, Yang DH, Zhu DL (2019) Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig\u00a0 10(2):399\u2013407. https:\/\/doi.org\/10.1111\/jdi.12888.\u00a0PMID: 29957886; PMCID: PMC6400178","DOI":"10.1111\/jdi.12888"},{"key":"3586_CR52","doi-asserted-by":"publisher","unstructured":"Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, Chen W, Yin T, Zhu D (2017) Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes 9(8):800\u2013809. https:\/\/doi.org\/10.1111\/1753-0407.12555.\u00a0PMID: 28332301","DOI":"10.1111\/1753-0407.12555"},{"key":"3586_CR53","doi-asserted-by":"publisher","unstructured":"Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, Kong R, Li L, Li J, Feng J, Wu L, Liu T, Xia Y, Lu J, Guo C, Zhou Y (2017) Metformin and diammonium glycyrrhizinate enteric-coated capsule versus metformin alone versus diammonium glycyrrhizinate enteric-coated capsule alone in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Gastroenterol Res Pract 2017:8491742. https:\/\/doi.org\/10.1155\/2017\/8491742.\u00a0PMID: 28133479; PMCID: PMC5241454","DOI":"10.1155\/2017\/8491742"},{"key":"3586_CR54","doi-asserted-by":"publisher","unstructured":"Yabiku K, Mutoh A, Miyagi K, Takasu N (2017) Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computed tomography and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease. Clin ther\u00a039(3):558\u2013566. https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.015.\u00a0PMID: 28185715","DOI":"10.1016\/j.clinthera.2017.01.015"},{"key":"3586_CR55","doi-asserted-by":"publisher","unstructured":"Zs\u00f3ri G, Ill\u00e9s D, Iv\u00e1ny E, Kos\u00e1r K, Holzinger G, Tajti M, P\u00e1link\u00e1s E, Szabovik G, Nagy A, Palk\u00f3 A, Czak\u00f3 L (2019) In new-onset diabetes mellitus, metformin reduces fat accumulation in the liver, but not in the pancreas or pericardium. Metab Syndr Relat Disord 17(5):289\u2013295. https:\/\/doi.org\/10.1089\/met.2018.0086.\u00a0PMID: 31013454","DOI":"10.1089\/met.2018.0086"},{"key":"3586_CR56","doi-asserted-by":"publisher","unstructured":"Vilar-Gomez E, Vuppalanchi R, Desai AP, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N (2019) Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 50(3):317\u2013328. https:\/\/doi.org\/10.1111\/apt.15331.\u00a0PMID: 31157422","DOI":"10.1111\/apt.15331"},{"key":"3586_CR57","doi-asserted-by":"publisher","unstructured":"Turner RC (1998) The U.K. prospective diabetes study. A review. Diabetes Care 21(Suppl 3):C35\u20138. https:\/\/doi.org\/10.2337\/diacare.21.3.c35.\u00a0PMID: 9850487","DOI":"10.2337\/diacare.21.3.c35"},{"key":"3586_CR58","doi-asserted-by":"publisher","unstructured":"Lee HW, Lee JS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU (2021) Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2\u202fyears. J Diabetes Complications 35(1):107747. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107747.\u00a0PMID: 33616043","DOI":"10.1016\/j.jdiacomp.2020.107747"},{"key":"3586_CR59","doi-asserted-by":"publisher","unstructured":"Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH (2009) Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther\u00a029(2):172\u201382. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03869.x.\u00a0PMID: 18945255 PMCID: PMC2990687","DOI":"10.1111\/j.1365-2036.2008.03869.x"},{"key":"3586_CR60","unstructured":"Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G (2013) Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med\u00a04(5):531\u20137. PMID: 23930163; PMCID: PMC3733183"},{"key":"3586_CR61","unstructured":"Shiasi Arani K, Taghavi Ardakani A, Moazami Goudarzi R, Talari HR, Hami K, Akbari H, Akbari N (2014) Effect of vitamin E and metformin on fatty liver disease in obese children- randomized clinical trial. Iran J Public Health 43(10):1417\u201323. PMID: 26060704; PMCID: PMC4441895"},{"issue":"4","key":"3586_CR62","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1665-2681(19)31902-7","volume":"6","author":"A Duseja","year":"2007","unstructured":"Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A (2007) Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann hepatol 6(4):222\u2013226. PMID: 18007551","journal-title":"Ann hepatol"},{"key":"3586_CR63","doi-asserted-by":"publisher","unstructured":"Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A (2010) Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 34(8):1255\u201364. https:\/\/doi.org\/10.1038\/ijo.2010.40.\u00a0PMID: 20179669","DOI":"10.1038\/ijo.2010.40"},{"key":"3586_CR64","doi-asserted-by":"publisher","unstructured":"\u0106ulafi\u0107 M, Vezmar-Kova\u010devi\u0107 S, Dopsaj V, Olui\u0107 B, Bid\u017ei\u0107 N, Miljkovi\u0107 B, \u0106ulafi\u0107 \u0110 (2020) Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. J Med Biochem 39(3):290\u2013298. https:\/\/doi.org\/10.2478\/jomb-2019-0043.\u00a0PMID: 33269017; PMCID: PMC7682853","DOI":"10.2478\/jomb-2019-0043"},{"key":"3586_CR65","doi-asserted-by":"publisher","unstructured":"Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E (2013) The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon 13(5):e9270. https:\/\/doi.org\/10.5812\/hepatmon.9270.\u00a0PMID: 23930133; PMCID: PMC3736624","DOI":"10.5812\/hepatmon.9270"},{"key":"3586_CR66","doi-asserted-by":"publisher","unstructured":"Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M (2011) Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 60(9):1278\u201384. https:\/\/doi.org\/10.1016\/j.metabol.2011.01.011.\u00a0PMID: 21411114","DOI":"10.1016\/j.metabol.2011.01.011"},{"key":"3586_CR67","doi-asserted-by":"publisher","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, \u00dcnalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR (2011) Nonalcoholic steatohepatitis clinical research network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:1659\u201368.\u00a0https:\/\/doi.org\/10.1001\/jama.2011.520.\u00a0PMID: 21521847; PMCID: PMC3110082","DOI":"10.1001\/jama.2011.520"},{"key":"3586_CR68","doi-asserted-by":"publisher","unstructured":"Haukeland JW, Konopski Z, Eggesb\u00f8 HB, von Volkmann HL, Raschpichler G, Bj\u00f8ro K, Haaland T, L\u00f8berg EM, Birkeland K (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44(7):853\u201360. https:\/\/doi.org\/10.1080\/00365520902845268.\u00a0PMID: 19811343","DOI":"10.1080\/00365520902845268"},{"key":"3586_CR69","doi-asserted-by":"publisher","unstructured":"Said A, Akhter A (2017) Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol 16(4):538\u2013547. https:\/\/doi.org\/10.5604\/01.3001.0010.0284.\u00a0PMID: 28611274","DOI":"10.5604\/01.3001.0010.0284"},{"key":"3586_CR70","doi-asserted-by":"publisher","unstructured":"Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N (2016) Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore) 95(32):e4529. https:\/\/doi.org\/10.1097\/MD.0000000000004529.\u00a0PMID: 27512874; PMCID: PMC4985329","DOI":"10.1097\/MD.0000000000004529"},{"key":"3586_CR71","doi-asserted-by":"publisher","unstructured":"Jalali M, Rahimlou M, Mahmoodi M, Moosavian SP, Symonds ME, Jalali R, Zare M, Imanieh MH, Stasi C (2020) The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: an up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 159:104799. https:\/\/doi.org\/10.1016\/j.phrs.2020.104799.\u00a0PMID: 32278041","DOI":"10.1016\/j.phrs.2020.104799"},{"key":"3586_CR72","doi-asserted-by":"publisher","unstructured":"Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL (2021) Effectiveness of drug interventions in nonalcoholic fatty liver disease: a network meta-analysis. World J Diabetes 12(9):1576\u20131586. https:\/\/doi.org\/10.4239\/wjd.v12.i9.1576.\u00a0PMID: 34630909; PMCID: PMC8472495","DOI":"10.4239\/wjd.v12.i9.1576"},{"key":"3586_CR73","doi-asserted-by":"publisher","unstructured":"Li Y, Liu L, Wang B, Wang J, Chen D (2013) Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep 2013; 1(1):57\u201364. https:\/\/doi.org\/10.3892\/br.2012.18.\u00a0PMID: 24648894; PMCID: PMC3956897","DOI":"10.3892\/br.2012.18"},{"key":"3586_CR74","doi-asserted-by":"publisher","unstructured":"Lian J, Fu J (2021) Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network meta-analysis. Front Endocrinol (Lausanne) 12:649018. https:\/\/doi.org\/10.3389\/fendo.2021.649018.\u00a0PMID: 33841337; PMCID: PMC8024567","DOI":"10.3389\/fendo.2021.649018"},{"key":"3586_CR75","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (EASL) (2016) European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59(6):1121\u201340. https:\/\/doi.org\/10.1007\/s00125-016-3902-y.\u00a0PMID: 27053230","DOI":"10.1007\/s00125-016-3902-y"},{"key":"3586_CR76","doi-asserted-by":"publisher","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z (2022) American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28(5):528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010.\u00a0PMID: 35569886","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"3586_CR77","doi-asserted-by":"publisher","unstructured":"Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F (2021) Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 18(1):24\u201339. https:\/\/doi.org\/10.1038\/s41575-020-00366-5.\u00a0PMID: 33093663","DOI":"10.1038\/s41575-020-00366-5"},{"key":"3586_CR78","doi-asserted-by":"publisher","unstructured":"Grygiel-G\u00f3rniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J 13:17. https:\/\/doi.org\/10.1186\/1475-2891-13-17.\u00a0PMID: 24524207; PMCID: PMC3943808","DOI":"10.1186\/1475-2891-13-17"},{"key":"3586_CR79","doi-asserted-by":"publisher","unstructured":"Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G (2018) Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opin Pharmacother 19(17):1903\u20131914. https:\/\/doi.org\/10.1080\/14656566.2018.1531126.\u00a0PMID: 30299993","DOI":"10.1080\/14656566.2018.1531126"},{"key":"3586_CR80","doi-asserted-by":"publisher","unstructured":"Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM (2006) Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 66(1):85\u2013109, Erratum in: drugs. 2006; 66(3):340\u20131. https:\/\/doi.org\/10.2165\/00003495-200666010-00005.\u00a0PMID: 16398569","DOI":"10.2165\/00003495-200666010-00005"},{"key":"3586_CR81","doi-asserted-by":"publisher","unstructured":"Kim HI, Ahn YH (2004) Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes 53:S60\u20135. https:\/\/doi.org\/10.2337\/diabetes.53.2007.s60.\u00a0PMID: 14749267","DOI":"10.2337\/diabetes.53.2007.s60"},{"key":"3586_CR82","doi-asserted-by":"publisher","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelli\u00e8re R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM (2008) PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299(13):1561\u201373. https:\/\/doi.org\/10.1001\/jama.299.13.1561.\u00a0PMID: 18378631","DOI":"10.1001\/jama.299.13.1561"},{"key":"3586_CR83","doi-asserted-by":"publisher","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lef\u00e8bvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Kor\u00e1nyi L, Laakso M, Mok\u00e1n M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U,\u00a0Taton J, PROactive investigators (2005)\u00a0Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366(9493):1279\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9.\u00a0PMID: 16214598","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"3586_CR84","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298(10):1180\u20138. https:\/\/doi.org\/10.1001\/jama.298.10.1180.\u00a0PMID: 17848652","DOI":"10.1001\/jama.298.10.1180"},{"key":"3586_CR85","doi-asserted-by":"publisher","unstructured":"DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE (2019) Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 16:133\u2013143. https:\/\/doi.org\/10.1177\/1479164118825376.\u00a0PMID: 30706731","DOI":"10.1177\/1479164118825376"},{"key":"3586_CR86","doi-asserted-by":"publisher","unstructured":"Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 71:17\u201332. https:\/\/doi.org\/10.1016\/j.metabol.2017.02.014.\u00a0PMID: 28521870","DOI":"10.1016\/j.metabol.2017.02.014"},{"key":"3586_CR87","doi-asserted-by":"publisher","unstructured":"Nayak IMN, Narendar K, M PA, Jamadar MG, Kumar VH. Comparison of pioglitazone and metformin efficacy against glucocorticoid induced atherosclerosis and hepatic steatosis in insulin resistant rats. J Clin Diagn Res 11(7):FC06-FC10. https:\/\/doi.org\/10.7860\/JCDR\/2017\/28418.10193.\u00a0PMID: 28892924 PMCID: PMC5583870","DOI":"10.7860\/JCDR\/2017\/28418.10193"},{"key":"3586_CR88","doi-asserted-by":"publisher","unstructured":"van der Veen JN, Lingrell S, Gao X, Quiroga AD, Takawale A, Armstrong EA, Yager JY, Kassiri Z, Lehner R, Vance DE, Jacobs RL (2016) Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. Am J Physiol Gastrointest Liver Physiol 310(7):G526\u201338. https:\/\/doi.org\/10.1152\/ajpgi.00243.2015.\u00a0PMID: 26797396","DOI":"10.1152\/ajpgi.00243.2015"},{"key":"3586_CR89","doi-asserted-by":"publisher","unstructured":"Kalavalapalli S, Bril F, Koelmel JP, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost RA, Frye RF, Garrett TJ, Cusi K, Sunny NE (2018) Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. Am J Physiol Endocrinol Metab 315(2):E163-E173. https:\/\/doi.org\/10.1152\/ajpendo.00023.2018.\u00a0PMID: 29634314 PMCID: PMC6139494","DOI":"10.1152\/ajpendo.00023.2018"},{"key":"3586_CR90","doi-asserted-by":"publisher","unstructured":"Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K (2004) Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 315:187\u201395. https:\/\/doi.org\/10.1016\/j.bbrc.2004.01.038.\u00a0PMID: 15013444","DOI":"10.1016\/j.bbrc.2004.01.038"},{"key":"3586_CR91","doi-asserted-by":"publisher","unstructured":"Deng W, Meng Z, Sun A, Yang Z (2017) Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: evidence from in vitro study. Cancer Biomark 20(4):411\u2013415. https:\/\/doi.org\/10.3233\/CBM-170157.\u00a0PMID: 28946547","DOI":"10.3233\/CBM-170157"},{"key":"3586_CR92","doi-asserted-by":"publisher","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297\u2013307. https:\/\/doi.org\/10.1056\/NEJMoa060326.\u00a0PMID: 17135584","DOI":"10.1056\/NEJMoa060326"},{"key":"3586_CR93","doi-asserted-by":"publisher","unstructured":"Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135(4):1176\u201384. https:\/\/doi.org\/10.1053\/j.gastro.2008.06.047.\u00a0PMID: 18718471","DOI":"10.1053\/j.gastro.2008.06.047"},{"key":"3586_CR94","doi-asserted-by":"publisher","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH,\u00a0Robuck PR, NASH CRN (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18):1675\u201385. https:\/\/doi.org\/10.1056\/NEJMoa0907929.\u00a0PMID: 20427778; PMCID: PMC2928471","DOI":"10.1056\/NEJMoa0907929"},{"key":"3586_CR95","doi-asserted-by":"publisher","unstructured":"Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK (2012) A randomized controlled trial comparing efficacy of\u00a0pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis. J Clin Exp Hepatol 2(4):333\u20137. https:\/\/doi.org\/10.1016\/j.jceh.2012.10.010.\u00a0PMID: 25755455; PMCID: PMC3940593","DOI":"10.1016\/j.jceh.2012.10.010"},{"key":"3586_CR96","doi-asserted-by":"publisher","unstructured":"Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H (2012) Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study. Hepat Mon 12(8):e6099. https:\/\/doi.org\/10.5812\/hepatmon.6099.\u00a0PMID: 23087748; PMCID: PMC3475019","DOI":"10.5812\/hepatmon.6099"},{"key":"3586_CR97","doi-asserted-by":"publisher","unstructured":"Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med\u00a0165(5):305\u201315. https:\/\/doi.org\/10.7326\/M15-1774.\u00a0PMID: 27322798","DOI":"10.7326\/M15-1774"},{"key":"3586_CR98","doi-asserted-by":"publisher","unstructured":"Yaghoubi M, Jafari S, Sajedi B, Gohari S, Akbarieh S, Heydari AH, Jameshoorani M (2017) Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol\u00a029(12):1385\u20131388.\u00a0\u00a0https:\/\/doi.org\/10.1097\/MEG.0000000000000981.\u00a0PMID: 29023319","DOI":"10.1097\/MEG.0000000000000981"},{"key":"3586_CR99","doi-asserted-by":"publisher","unstructured":"Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, Akiyama Y, Morimoto Y, Noda M, Shimada A (2017) Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes care\u00a040:1364\u20131372. https:\/\/doi.org\/10.2337\/dc17-0518.\u00a0PMID: 28751548","DOI":"10.2337\/dc17-0518"},{"key":"3586_CR100","doi-asserted-by":"publisher","unstructured":"Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H (2021) Favorable effect of sodium-glucose cotransporter\u00a02 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig 12:1272\u20131277. https:\/\/doi.org\/10.1111\/jdi.13457.\u00a0PMID: 33131199; PMCID: PMC8264405","DOI":"10.1111\/jdi.13457"},{"key":"3586_CR101","doi-asserted-by":"publisher","unstructured":"Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, Tatsumi F, Hirukawa H, Sanada J, Kohara K, Irie S, Kimura T, Nakamura Y, Nishioka M, Obata A, Nakanishi S, Mune T, Kaku K, Kaneto H (2020) Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig\u00a011:1612\u20131622.\u00a0https:\/\/doi.org\/10.1111\/jdi.13279.\u00a0PMID: 32329963; PMCID: PMC7610105","DOI":"10.1111\/jdi.13279"},{"key":"3586_CR102","doi-asserted-by":"publisher","unstructured":"Zhang LY, Qu XN, Sun ZY, Zhang Y (2020) Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 44(5):674\u2013680. https:\/\/doi.org\/10.1016\/j.clinre.2020.01.007.\u00a0PMID: 32113823","DOI":"10.1016\/j.clinre.2020.01.007"},{"issue":"7","key":"3586_CR103","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.36740\/WLek202107112","volume":"74","author":"VP Shypulin","year":"2021","unstructured":"Shypulin VP, Martynchuk OA, Rudenko NN, Koliada AK, Tishchenko VV, Melnyk NH (2021) Association analysis of pioglitazone effectiveness in treatment of NAFLD patients with obesity and PPARG RS1801282 (PRO12ALA) genotype. Wiad Lek 74(7):1617\u20131621. PMID: 34459761","journal-title":"Wiad Lek"},{"key":"3586_CR104","doi-asserted-by":"publisher","unstructured":"Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, Taguri M, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A (2021) Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care\u00a09(1):e001990. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001990.\u00a0PMID: 33593749; PMCID: PMC7888333","DOI":"10.1136\/bmjdrc-2020-001990"},{"key":"3586_CR105","doi-asserted-by":"publisher","unstructured":"Della Pepa G, Russo M, Vitale M, Carli F, Vetrani C, Masulli M, Riccardi G, Vaccaro O, Gastaldelli A, Rivellese AA, Bozzetto L (2021) Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract\u00a0178:108984. https:\/\/doi.org\/10.1016\/j.diabres.2021.108984.\u00a0PMID: 34311022","DOI":"10.1016\/j.diabres.2021.108984"},{"key":"3586_CR106","doi-asserted-by":"publisher","unstructured":"Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K (2021) PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int\u00a041:2659\u20132670. https:\/\/doi.org\/10.1111\/liv.15005.\u00a0PMID: 34219361; PMCID: PMC9290929","DOI":"10.1111\/liv.15005"},{"key":"3586_CR107","doi-asserted-by":"publisher","unstructured":"Yoneda M, Kobayashi T, Honda Y, Ogawa Y, Kessoku T, Imajo K, Nogami A, Taguri M, Kirikoshi H, Saito S, Nakajima A (2022) Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial. Hepatol commun\u00a06(9):2273\u20132285. https:\/\/doi.org\/10.1002\/hep4.1993.\u00a0PMID: 35578445; PMCID: PMC9426404","DOI":"10.1002\/hep4.1993"},{"key":"3586_CR108","doi-asserted-by":"publisher","unstructured":"Blazina I, Selph S (2019) Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev\u00a08:295. https:\/\/doi.org\/10.1186\/s13643-019-1200-8.\u00a0PMID: 31783920; PMCID: PMC6884753","DOI":"10.1186\/s13643-019-1200-8"},{"key":"3586_CR109","doi-asserted-by":"publisher","unstructured":"Lian J, Fu J (2022) Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front endocrinol (Lausanne) 2021; 12:615409. Erratum in: Front Endocrinol (Lausanne)\u00a013:840299.\u00a0https:\/\/doi.org\/10.3389\/fendo.2021.615409.\u00a0PMID: 33995271; PMCID: PMC8115121","DOI":"10.3389\/fendo.2021.615409"},{"key":"3586_CR110","doi-asserted-by":"publisher","unstructured":"Albert SG, Wood EM (2021) Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome. Diabetes Metab Syndr 15(5):102232. https:\/\/doi.org\/10.1016\/j.dsx.2021.102232.\u00a0PMID: 34352720","DOI":"10.1016\/j.dsx.2021.102232"},{"key":"3586_CR111","doi-asserted-by":"publisher","unstructured":"Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R (2021) Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther\u00a054:880\u2013889. https:\/\/doi.org\/10.1111\/apt.16583.\u00a0PMID: 34435378; PMCID: PMC8711247","DOI":"10.1111\/apt.16583"},{"key":"3586_CR112","doi-asserted-by":"publisher","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177(5):633\u2013640. Erratum in: JAMA Intern Med 177(5):747. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607.\u00a0PMID: 28241279; PMCID: PMC5470366","DOI":"10.1001\/jamainternmed.2016.9607"},{"key":"3586_CR113","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med\u00a0383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190.\u00a0PMID: 32865377","DOI":"10.1056\/NEJMoa2022190"},{"key":"3586_CR114","doi-asserted-by":"publisher","unstructured":"Levin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, Koitka-Weber A, Wanner C, EMPA-REG outcome investigators (2020) Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial. Clin J Am Soc Nephrol\u00a015(10):1433\u20131444. https:\/\/doi.org\/10.2215\/CJN.14901219.\u00a0PMID: 32994159; PMCID: PMC7536760","DOI":"10.2215\/CJN.14901219"},{"key":"3586_CR115","doi-asserted-by":"publisher","unstructured":"van der Aart-van der Beek AB, de Boer RA, Heerspink HJL (2022) Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol\u00a018(5):294\u2013306. https:\/\/doi.org\/10.1038\/s41581-022-00535-6.\u00a0PMID: 35145275","DOI":"10.1038\/s41581-022-00535-6"},{"key":"3586_CR116","doi-asserted-by":"publisher","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet\u00a0396(10254):819\u2013829. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9.\u00a0PMID: 32877652","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"3586_CR117","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, B\u00f6hm M, Ferreira JP, Pocock SJ, Zannad F, Packer M (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation\u00a0143:337\u2013349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051824.\u00a0PMID: 33175585; PMCID: PMC7834911","DOI":"10.1161\/CIRCULATIONAHA.120.051824"},{"key":"3586_CR118","doi-asserted-by":"publisher","unstructured":"Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M (2016) Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care\u00a039(11):2036\u20132041. https:\/\/doi.org\/10.2337\/dc15-2688.\u00a0PMID: 27561923; PMCID: PMC5079607","DOI":"10.2337\/dc15-2688"},{"key":"3586_CR119","doi-asserted-by":"publisher","unstructured":"Wang D, Luo Y, Wang X, Orlicky DJ, Myakala K, Yang P, Levi M (2018) The Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice. Int J Mol Sci\u00a019:137. https:\/\/doi.org\/10.3390\/ijms19010137.\u00a0PMID: 29301371; PMCID: PMC5796086","DOI":"10.3390\/ijms19010137"},{"key":"3586_CR120","doi-asserted-by":"publisher","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Th\u00e9venet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med\u00a021(5):512\u20137. https:\/\/doi.org\/10.1038\/nm.3828.\u00a0PMID: 25894829","DOI":"10.1038\/nm.3828"},{"key":"3586_CR121","doi-asserted-by":"publisher","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E (2016) Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes\u00a065(5):1190\u20135. https:\/\/doi.org\/10.2337\/db15-1356.\u00a0PMID: 26861783","DOI":"10.2337\/db15-1356"},{"key":"3586_CR122","doi-asserted-by":"publisher","unstructured":"Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol\u00a0727:66\u201374. https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.040.\u00a0PMID: 24486393","DOI":"10.1016\/j.ejphar.2014.01.040"},{"key":"3586_CR123","doi-asserted-by":"publisher","unstructured":"Steven S, Oelze M, Hanf A, Kr\u00f6ller-Sch\u00f6n S, Kashani F, Roohani S, Welschof P, Kopp M, G\u00f6dtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, M\u00fcnzel T, Daiber A (2017) The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol\u00a013:370\u2013385. https:\/\/doi.org\/10.1016\/j.redox.2017.06.009.\u00a0PMID: 28667906; PMCID: PMC5491464","DOI":"10.1016\/j.redox.2017.06.009"},{"key":"3586_CR124","doi-asserted-by":"publisher","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS One\u00a09(6):e100777. https:\/\/doi.org\/10.1371\/journal.pone.0100777.\u00a0PMID: 24960177; PMCID: PMC4069074","DOI":"10.1371\/journal.pone.0100777"},{"key":"3586_CR125","doi-asserted-by":"publisher","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M (2014) Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol\u00a066:975\u201387. https:\/\/doi.org\/10.1111\/jphp.12223.\u00a0PMID: 24533859","DOI":"10.1111\/jphp.12223"},{"key":"3586_CR126","doi-asserted-by":"publisher","unstructured":"Yaribeygi H, Atkin SL, Butler AE, Sahebkar A (2019) Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol\u00a0234:3231\u20133237. https:\/\/doi.org\/10.1002\/jcp.26760.\u00a0PMID: 30443936","DOI":"10.1002\/jcp.26760"},{"key":"3586_CR127","doi-asserted-by":"publisher","unstructured":"Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, Yano T, Nakata K, Kimura Y, Abe K, Ohwada W, Miura T (2019) Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther\u00a0368:524\u2013534. https:\/\/doi.org\/10.1124\/jpet.118.253666.\u00a0PMID: 30552292","DOI":"10.1124\/jpet.118.253666"},{"key":"3586_CR128","doi-asserted-by":"publisher","unstructured":"Petito-da-Silva TI, Souza-Mello V, Barbosa-da-Silva S (2019) Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol Cell Endocrinol\u00a0498:110539. https:\/\/doi.org\/10.1016\/j.mce.2019.110539.\u00a0PMID: 31419466","DOI":"10.1016\/j.mce.2019.110539"},{"key":"3586_CR129","doi-asserted-by":"publisher","unstructured":"Chen Z, Liu Y, Yang L, Liu P, Zhang Y, Wang X (2020) MiR-149 attenuates endoplasmic reticulum stress-induced inflammation and apoptosis in nonalcoholic fatty liver disease by negatively targeting ATF6 pathway. Immunol Lett\u00a0222:40\u201348. https:\/\/doi.org\/10.1016\/j.imlet.2020.03.003.\u00a0PMID: 32194141","DOI":"10.1016\/j.imlet.2020.03.003"},{"key":"3586_CR130","doi-asserted-by":"publisher","unstructured":"Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, Sawada Y, Saikawa S, Kitagawa K, Takaya H, Kawaratani H, Kitade M, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H (2020) Combined treatment with sodium-glucose cotransporter-2 inhibitor (canagliflozin) and dipeptidyl peptidase-4 inhibitor (teneligliptin) alleviates NASH progression in a non-diabetic rat model of steatohepatitis. Int J Mol Sci\u00a021(6):2164. https:\/\/doi.org\/10.3390\/ijms21062164.\u00a0PMID: 32245205; PMCID: PMC7139722","DOI":"10.3390\/ijms21062164"},{"key":"3586_CR131","doi-asserted-by":"publisher","unstructured":"Shiba K, Tsuchiya K, Komiya C, Miyachi Y, Mori K, Shimazu N, Yamaguchi S, Ogasawara N, Katoh M, Itoh M, Suganami T, Ogawa Y (2018) Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep\u00a08:2362. https:\/\/doi.org\/10.1038\/s41598-018-19658-7.\u00a0PMID: 29402900; PMCID: PMC5799179","DOI":"10.1038\/s41598-018-19658-7"},{"key":"3586_CR132","doi-asserted-by":"publisher","unstructured":"Bando Y, Ogawa A, Ishikura K, Kanehara H, Hisada A, Notumata K, Okafuji K, Toya D (2017) The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetol Int\u00a08(2):218\u2013227. https:\/\/doi.org\/10.1007\/s13340-016-0302-y.\u00a0PMID: 30603325; PMCID: PMC6224952","DOI":"10.1007\/s13340-016-0302-y"},{"key":"3586_CR133","doi-asserted-by":"publisher","unstructured":"Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y (2017) Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res\u00a047:1072\u20131078. https:\/\/doi.org\/10.1111\/hepr.12834.\u00a0PMID: 27925353","DOI":"10.1111\/hepr.12834"},{"key":"3586_CR134","doi-asserted-by":"publisher","unstructured":"Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H (2017) Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun\u00a01:46\u201352. https:\/\/doi.org\/10.1002\/hep4.1019.\u00a0PMID: 29404432; PMCID: PMC5747031","DOI":"10.1002\/hep4.1019"},{"key":"3586_CR135","doi-asserted-by":"publisher","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnstr\u00f6m M, Moris L, Miliotis T, Forsberg GB, Ris\u00e9rus U, Lind L, Oscarsson J (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia\u00a061:1923\u20131934. https:\/\/doi.org\/10.1007\/s00125-018-4675-2.\u00a0PMID: 29971527; PMCID: PMC6096619","DOI":"10.1007\/s00125-018-4675-2"},{"key":"3586_CR136","doi-asserted-by":"publisher","unstructured":"Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R (2018) SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes. Diabetes Metab\u00a044(6):493\u2013499.\u00a0https:\/\/doi.org\/10.1016\/j.diabet.2018.08.001.\u00a0PMID: 30149145","DOI":"10.1016\/j.diabet.2018.08.001"},{"key":"3586_CR137","doi-asserted-by":"publisher","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care\u00a041:1801\u20131808. https:\/\/doi.org\/10.2337\/dc18-0165.\u00a0PMID: 29895557","DOI":"10.2337\/dc18-0165"},{"key":"3586_CR138","doi-asserted-by":"publisher","unstructured":"Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, Kawai H, Ohashi N, Mori A (2018) Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab\u00a020(2):438\u2013442. https:\/\/doi.org\/10.1111\/dom.13061.\u00a0PMID: 28719078","DOI":"10.1111\/dom.13061"},{"key":"3586_CR139","doi-asserted-by":"publisher","unstructured":"Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY (2018) Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease. Endocrinol Metab (Seoul)\u00a033(3):387\u2013394.\u00a0https:\/\/doi.org\/10.3803\/EnM.2018.33.3.387.\u00a0PMID: 30229578; PMCID: PMC6145967","DOI":"10.3803\/EnM.2018.33.3.387"},{"key":"3586_CR140","doi-asserted-by":"publisher","unstructured":"Itani T, Ishihara T (2018) Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract\u00a04:477\u2013482. https:\/\/doi.org\/10.1002\/osp4.294.\u00a0PMID: 30338118; PMCID: PMC6180715","DOI":"10.1002\/osp4.294"},{"key":"3586_CR141","doi-asserted-by":"publisher","unstructured":"Miyake T, Yoshida S, Furukawa S, Sakai T, Tada F, Senba H, Yamamoto S, Koizumi Y, Yoshida O, Hirooka M, Kumagi T, Niiya T, Miyaoka H, Masanori A, Matsuura B, Hiasa Y (2018) Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars)\u00a013:402\u2013409. https:\/\/doi.org\/10.1515\/med-2018-0059.\u00a0PMID: 30234161; PMCID: PMC6141887","DOI":"10.1515\/med-2018-0059"},{"issue":"2","key":"3586_CR142","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y (2019) Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21(2):285\u2013292. https:\/\/doi.org\/10.1111\/dom.13520. PMID: 30178600","journal-title":"Diabetes Obes Metab"},{"key":"3586_CR143","doi-asserted-by":"publisher","unstructured":"Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, Osonoi T (2019) Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial). Hepatol Res\u00a049(1):64\u201371. Erratum in: Hepatol Res\u00a049:957. https:\/\/doi.org\/10.1111\/hepr.13236.\u00a0PMID: 30051943","DOI":"10.1111\/hepr.13236"},{"key":"3586_CR144","doi-asserted-by":"publisher","unstructured":"Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H (2019) Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res\u00a049(5):531\u2013539.\u00a0https:\/\/doi.org\/10.1111\/hepr.13304.\u00a0PMID: 30577089","DOI":"10.1111\/hepr.13304"},{"key":"3586_CR145","doi-asserted-by":"publisher","unstructured":"Yamashima M, Miyaaki H, Miuma S, Shibata H, Sasaki R, Haraguchi M, Fukushima M, Nakao K (2019) The long-term efficacy of sodium glucose co-transporter 2 inhibitor in patients with non-alcoholic fatty liver disease. Intern Med\u00a058:1987\u20131992. https:\/\/doi.org\/10.2169\/internalmedicine.2566-18.\u00a0PMID: 31308341; PMCID: PMC6702010","DOI":"10.2169\/internalmedicine.2566-18"},{"key":"3586_CR146","doi-asserted-by":"publisher","unstructured":"Han E, Lee YH, Lee BW, Kang ES, Cha BS (2020) Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial. J Clin Med\u00a09:259. https:\/\/doi.org\/10.3390\/jcm9010259.\u00a0PMID: 31963648; PMCID: PMC7019437","DOI":"10.3390\/jcm9010259"},{"key":"3586_CR147","doi-asserted-by":"publisher","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, van Gemert T, Knebel B, Wolkersdorfer MF, Kuss O, Hwang JH, Bornstein SR, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld AL, Roden M (2020) Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43:298\u2013305. https:\/\/doi.org\/10.2337\/dc19-0641. PMID: 31540903","DOI":"10.2337\/dc19-0641"},{"key":"3586_CR148","doi-asserted-by":"publisher","unstructured":"Mittag-Roussou V, Wagenpfeil S, Lammert F, Stokes CS (2020) Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. Endocrinol Diabetes Metab\u00a03:e00131. https:\/\/doi.org\/10.1002\/edm2.131.\u00a0PMID: 32704556 PMCID: PMC7375113","DOI":"10.1002\/edm2.131"},{"key":"3586_CR149","doi-asserted-by":"publisher","unstructured":"Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H (2020) SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology. Intern Med\u00a059(16):1931\u20131937. https:\/\/doi.org\/10.2169\/internalmedicine.4398-19.\u00a0PMID: 32448832; PMCID: PMC7492114","DOI":"10.2169\/internalmedicine.4398-19"},{"key":"3586_CR150","doi-asserted-by":"publisher","unstructured":"Euh W, Lim S, Kim JW (2021) Sodium-glucose cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Front Endocrinol (Lausanne)\u00a012:613389. https:\/\/doi.org\/10.3389\/fendo.2021.613389.\u00a0PMID: 34177796; PMCID: PMC8222919","DOI":"10.3389\/fendo.2021.613389"},{"key":"3586_CR151","doi-asserted-by":"publisher","unstructured":"Colosimo S, Ravaioli F, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L (2021) Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real-world data analysis. Liver Int\u00a041:731\u2013742. https:\/\/doi.org\/10.1111\/liv.14799.\u00a0PMID: 33497019; PMCID: PMC8248247","DOI":"10.1111\/liv.14799"},{"key":"3586_CR152","doi-asserted-by":"publisher","unstructured":"Tobita H, Yazaki T, Kataoka M, Kotani S, Oka A, Mishiro T, Oshima N, Kawashima K, Ishimura N, Naora K, Sato S, Ishihara S (2021) Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. J Clin Biochem Nutr\u00a068(2):173\u2013180. https:\/\/doi.org\/10.3164\/jcbn.20-129.\u00a0PMID: 33879970; PMCID: PMC8046003","DOI":"10.3164\/jcbn.20-129"},{"key":"3586_CR153","doi-asserted-by":"publisher","unstructured":"Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, Isoda H, Oeda S, Kurai O, Yoneda M, Ono M, Kitajima Y, Tajiri R, Takamori A, Kawaguchi A, Aishima S, Kage M, Nakajima A, Eguchi Y, Anzai K (2022) Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun\u00a06:120\u2013132. https:\/\/doi.org\/10.1002\/hep4.1696.\u00a0PMID: 34558835; PMCID: PMC8710792","DOI":"10.1002\/hep4.1696"},{"key":"3586_CR154","doi-asserted-by":"publisher","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah AE, Khamseh ME (2021) Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther\u00a012(3):843\u2013861. https:\/\/doi.org\/10.1007\/s13300-021-01011-3.\u00a0PMID: 33586120 PMCID: PMC7882235","DOI":"10.1007\/s13300-021-01011-3"},{"key":"3586_CR155","doi-asserted-by":"publisher","unstructured":"Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, Lasbleiz A, Peiretti F, Bornet CE, Lefur Y, Pini L, Rapacchi S, Bernard M, Resseguier N, Darmon P, Kober F, Dutour A (2021) Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol 20(1):57. https:\/\/doi.org\/10.1186\/s12933-021-01237-2.\u00a0PMID: 33648515; PMCID: PMC7919089","DOI":"10.1186\/s12933-021-01237-2"},{"key":"3586_CR156","doi-asserted-by":"publisher","unstructured":"Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K (2021) Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab 12:20420188211000243. https:\/\/doi.org\/10.1177\/20420188211000243.\u00a0PMID: 33815743; PMCID: PMC7989116","DOI":"10.1177\/20420188211000243"},{"key":"3586_CR157","doi-asserted-by":"publisher","unstructured":"Pradhan R, Yin H, Yu O, Azoulay L (2022) Glucagon-Like Peptide 1 Receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care 45(4):819\u2013829. https:\/\/doi.org\/10.2337\/dc21-1953.\u00a0PMID: 35104330","DOI":"10.2337\/dc21-1953"},{"key":"3586_CR158","doi-asserted-by":"publisher","unstructured":"Sinha B, Datta D, Ghosal S (2020) Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes. JGH Open 5(2):219\u2013227. https:\/\/doi.org\/10.1002\/jgh3.12473.\u00a0PMID: 33553659; PMCID: PMC7857274","DOI":"10.1002\/jgh3.12473"},{"key":"3586_CR159","doi-asserted-by":"publisher","unstructured":"Mo M, Huang Z, Liang Y, Liao Y, Xia N (2022) The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: an updated meta-analysis. Dig Liver Dis 54:461\u2013468. https:\/\/doi.org\/10.1016\/j.dld.2021.08.017.\u00a0PMID: 34507895","DOI":"10.1016\/j.dld.2021.08.017"},{"key":"3586_CR160","doi-asserted-by":"publisher","unstructured":"Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM (2021) Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis. Front Endocrinol (Lausanne) 11:609135. https:\/\/doi.org\/10.3389\/fendo.2020.609135.\u00a0PMID: 33643221; PMCID: PMC7905212","DOI":"10.3389\/fendo.2020.609135"},{"key":"3586_CR161","doi-asserted-by":"publisher","unstructured":"Aroda VR (2018) A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab\u00a020:22\u201333. https:\/\/doi.org\/10.1111\/dom.13162.\u00a0PMID: 29364586","DOI":"10.1111\/dom.13162"},{"key":"3586_CR162","doi-asserted-by":"publisher","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R (2015) User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med 127:818\u201326. https:\/\/doi.org\/10.1080\/00325481.2015.1090295.\u00a0PMID: 26371721","DOI":"10.1080\/00325481.2015.1090295"},{"key":"3586_CR163","doi-asserted-by":"publisher","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology\u00a0132:2131\u201357. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054.\u00a0PMID: 17498508","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"3586_CR164","doi-asserted-by":"publisher","unstructured":"Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S (2011) Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol\u00a054:1214\u201323. https:\/\/doi.org\/10.1016\/j.jhep.2010.09.032.\u00a0PMID: 21145820","DOI":"10.1016\/j.jhep.2010.09.032"},{"key":"3586_CR165","doi-asserted-by":"publisher","unstructured":"Khan RS, Bril F, Cusi K, Newsome PN (2019) Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology\u00a070:711\u2013724. https:\/\/doi.org\/10.1002\/hep.30429.\u00a0PMID: 30556145","DOI":"10.1002\/hep.30429"},{"key":"3586_CR166","doi-asserted-by":"publisher","unstructured":"Yan H, Huang C, Shen X, Li J, Zhou S, Li W (2022) GLP-1 RAs and SGLT-2 inhibitors for insulin resistance in nonalcoholic fatty liver disease: systematic review and network meta-analysis. Front Endocrinol (Lausanne)\u00a013:923606. https:\/\/doi.org\/10.3389\/fendo.2022.923606.\u00a0PMID: 35909522; PMCID: PMC9325993","DOI":"10.3389\/fendo.2022.923606"},{"key":"3586_CR167","doi-asserted-by":"publisher","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology\u00a051(5):1584\u201392. https:\/\/doi.org\/10.1002\/hep.23569.\u00a0PMID: 20225248; PMCID: PMC2862093","DOI":"10.1002\/hep.23569"},{"key":"3586_CR168","doi-asserted-by":"publisher","unstructured":"Liu Y, Wei R, Hong TP (2014) Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol\u00a020:9090\u20137. https:\/\/doi.org\/10.3748\/wjg.v20.i27.9090.\u00a0PMID: 25083081; PMCID: PMC4115340","DOI":"10.3748\/wjg.v20.i27.9090"},{"key":"3586_CR169","doi-asserted-by":"publisher","unstructured":"Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One\u00a07:e50117. https:\/\/doi.org\/10.1371\/journal.pone.0050117.\u00a0PMID: 23236362 PMCID: PMC3516516","DOI":"10.1371\/journal.pone.0050117"},{"key":"3586_CR170","doi-asserted-by":"publisher","first-page":"496453","DOI":"10.1100\/2012\/496453","volume":"2012","author":"T Ohki","year":"2012","unstructured":"Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K (2012) The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci World J 2012:496453. https:\/\/doi.org\/10.1100\/2012\/496453","journal-title":"Sci World J"},{"key":"3586_CR171","doi-asserted-by":"publisher","unstructured":"Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD) (2015) Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res\u00a045:269\u201378. https:\/\/doi.org\/10.1111\/hepr.12351.\u00a0PMID: 24796231","DOI":"10.1111\/hepr.12351"},{"key":"3586_CR172","doi-asserted-by":"publisher","unstructured":"Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64:399\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.038.\u00a0PMID: 26394161; PMCID: PMC4713865","DOI":"10.1016\/j.jhep.2015.08.038"},{"key":"3586_CR173","doi-asserted-by":"publisher","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, H\u00fcbscher SG, Newsome PN (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet\u00a0387:679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.\u00a0PMID: 26608256","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"3586_CR174","doi-asserted-by":"publisher","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pouwels PJ, Pieters-van den Bos IC, Hoekstra T, Diamant M, van Raalte DH, Cahen DL (2016) Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia\u00a059:2588\u20132593. https:\/\/doi.org\/10.1007\/s00125-016-4100-7.\u00a0PMID: 27627981; PMCID: PMC6518065","DOI":"10.1007\/s00125-016-4100-7"},{"key":"3586_CR175","doi-asserted-by":"publisher","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J (2018) Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab\u00a020:215\u2013218. https:\/\/doi.org\/10.1111\/dom.13053.\u00a0PMID: 28681988","DOI":"10.1111\/dom.13053"},{"key":"3586_CR176","doi-asserted-by":"publisher","unstructured":"Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Verg\u00e8s B (2017) Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab\u00a0102:407\u2013415. https:\/\/doi.org\/10.1210\/jc.2016-2775.\u00a0PMID: 27732328","DOI":"10.1210\/jc.2016-2775"},{"key":"3586_CR177","doi-asserted-by":"publisher","unstructured":"Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y (2017) Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J\u00a064:269\u2013281. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0449.\u00a0PMID: 27916783","DOI":"10.1507\/endocrj.EJ16-0449"},{"key":"3586_CR178","doi-asserted-by":"publisher","unstructured":"Khoo J, Hsiang J, Taneja R, Law NM, Ang TL (2017) Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. Diabetes Obes Metab\u00a019:1814\u20131817. https:\/\/doi.org\/10.1111\/dom.13007.\u00a0PMID: 28503750","DOI":"10.1111\/dom.13007"},{"key":"3586_CR179","doi-asserted-by":"publisher","unstructured":"Tian F, Zheng Z, Zhang D, He S, Shen J (2018) Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Biosci Rep\u00a038:BSR20181304. https:\/\/doi.org\/10.1042\/BSR20181304.\u00a0PMID: 30473540; PMCID: PMC6435530","DOI":"10.1042\/BSR20181304"},{"key":"3586_CR180","doi-asserted-by":"publisher","unstructured":"Zhang Z, Qi Y, Kong W, Jin Q, Wang X, Dong Y, Wang Y, Li H (2018) Efficacy and clinical value of liraglutide for treatment of diabetes mellitus complicated by non-alcoholic fatty liver disease. Med Sci Monit\u00a024:7399\u20137404. https:\/\/doi.org\/10.12659\/MSM.911062.\u00a0PMID: 30325900; PMCID: PMC6199821","DOI":"10.12659\/MSM.911062"},{"key":"3586_CR181","doi-asserted-by":"publisher","unstructured":"Cusi K, Sattar N, Garc\u00eda-P\u00e9rez LE, Pavo I, Yu M, Robertson KE, Karanikas CA, Haupt A (2018) Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med\u00a035:1434\u20131439. https:\/\/doi.org\/10.1111\/dme.13697.\u00a0PMID: 29869810","DOI":"10.1111\/dme.13697"},{"key":"3586_CR182","doi-asserted-by":"publisher","unstructured":"Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J (2019) Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology\u00a069:2414\u20132426. https:\/\/doi.org\/10.1002\/hep.30320.\u00a0PMID: 30341767; PMCID: PMC6594101","DOI":"10.1002\/hep.30320"},{"key":"3586_CR183","doi-asserted-by":"publisher","unstructured":"Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, Law NM, Ang TL (2019) Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int\u00a039:941\u2013949. https:\/\/doi.org\/10.1111\/liv.14065.\u00a0PMID: 30721572","DOI":"10.1111\/liv.14065"},{"key":"3586_CR184","doi-asserted-by":"publisher","unstructured":"Guo W, Tian W, Lin L, Xu X (2020) Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract\u00a0170:108487. https:\/\/doi.org\/10.1016\/j.diabres.2020.108487.\u00a0PMID: 33035599","DOI":"10.1016\/j.diabres.2020.108487"},{"key":"3586_CR185","doi-asserted-by":"publisher","unstructured":"Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, Polyzos SA (2020) Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr\u00a014:1913\u20131919. https:\/\/doi.org\/10.1016\/j.dsx.2020.09.030.\u00a0PMID: 33011499","DOI":"10.1016\/j.dsx.2020.09.030"},{"key":"3586_CR186","doi-asserted-by":"publisher","unstructured":"Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, G\u00f8rtz PM, Holst JJ, Gr\u00f8nb\u00e6k H, Svare JA, Clausen TD, Mathiesen ER, Damm P, Gluud LL, Knop FK, Vilsb\u00f8ll T (2020) One year\u2019s treatment with the glucagon-like peptide 1 receptor agonist liraglutide decreases hepatic fat content in women with nonalcoholic fatty liver disease and prior gestational diabetes mellitus in a randomized, placebo-controlled trial. J Clin Med\u00a09:3213.\u00a0https:\/\/doi.org\/10.3390\/jcm9103213.\u00a0PMID: 33036179; PMCID: PMC7601647","DOI":"10.3390\/jcm9103213"},{"key":"3586_CR187","doi-asserted-by":"publisher","unstructured":"Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, Kaur P, Gill HK, Bano T, Farooqui KJ, Mithal A (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia\u00a063:2434\u20132445. https:\/\/doi.org\/10.1007\/s00125-020-05265-7.\u00a0PMID: 32865597","DOI":"10.1007\/s00125-020-05265-7"},{"key":"3586_CR188","doi-asserted-by":"publisher","unstructured":"Shiomi M, Tanaka Y, Takada T, Otori K (2020) Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. JGH Open\u00a04:995\u20131001. https:\/\/doi.org\/10.1002\/jgh3.12384.\u00a0PMID: 33102775; PMCID: PMC7578289","DOI":"10.1002\/jgh3.12384"},{"key":"3586_CR189","doi-asserted-by":"publisher","unstructured":"Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N, Rao S, Yao X, Wu W, Pan B, Bian H, Gao X (2020) Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36:e3292. https:\/\/doi.org\/10.1002\/dmrr.3292. Epub 2020 Feb 10.\u00a0PMID: 31955491","DOI":"10.1002\/dmrr.3292"},{"key":"3586_CR190","doi-asserted-by":"publisher","unstructured":"Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW (2020) Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia\u00a063:65\u201374. https:\/\/doi.org\/10.1007\/s00125-019-05021-6.\u00a0PMID: 31690988; PMCID: PMC6890592","DOI":"10.1007\/s00125-019-05021-6"},{"key":"3586_CR191","doi-asserted-by":"publisher","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931\u20134296 Investigators (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med\u00a0384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395.\u00a0PMID: 33185364","DOI":"10.1056\/NEJMoa2028395"},{"key":"3586_CR192","doi-asserted-by":"publisher","unstructured":"Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-M\u00f6rschel L (2021) Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 54: 1150\u20131161. https:\/\/doi.org\/10.1111\/apt.16608.\u00a0PMID: 34570916; PMCID: PMC9292692","DOI":"10.1111\/apt.16608"},{"key":"3586_CR193","doi-asserted-by":"publisher","unstructured":"Li X, Wu X, Jia Y, Fu J, Zhang L, Jiang T, Liu J, Wang G (2021) Liraglutide decreases liver fat content and serum fibroblast growth factor 21 levels in newly diagnosed overweight patients with type 2 diabetes and nonalcoholic fatty liver disease. J Diabetes Res\u00a02021:3715026. https:\/\/doi.org\/10.1155\/2021\/3715026.\u00a0PMID: 34660809; PMCID: PMC8519721","DOI":"10.1155\/2021\/3715026"},{"key":"3586_CR194","doi-asserted-by":"publisher","unstructured":"Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, Klepochova R, Kr\u0161\u0161\u00e1k M, Kautzky-Willer A (2021) Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Diabetes Obes Metab 23:1129\u20131139. https:\/\/doi.org\/10.1111\/dom.14319.\u00a0PMID: 33464703; PMCID: PMC8247845","DOI":"10.1111\/dom.14319"},{"key":"3586_CR195","doi-asserted-by":"publisher","unstructured":"Arai T, Atsukawa M, Tsubota A, Ono H, Kawano T, Yoshida Y, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Nagao M, Iwakiri K (2022) Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: a pilot study. JGH Open 6:503\u2013511.\u00a0https:\/\/doi.org\/10.1002\/jgh3.12780.\u00a0PMID: 35822119; PMCID: PMC9260206","DOI":"10.1002\/jgh3.12780"},{"key":"3586_CR196","doi-asserted-by":"publisher","unstructured":"Zhu Y, Xu J, Zhang D, Mu X, Shi Y, Chen S, Wu Z, Li S (2021) Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne)\u00a012:769069. https:\/\/doi.org\/10.3389\/fendo.2021.769069.\u00a0PMID: 34956080; PMCID: PMC8696030","DOI":"10.3389\/fendo.2021.769069"},{"key":"3586_CR197","doi-asserted-by":"publisher","unstructured":"Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 investigators (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA\u00a0327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619.\u00a0PMID: 35015037; PMCID: PMC8753508","DOI":"10.1001\/jama.2021.23619"},{"key":"3586_CR198","doi-asserted-by":"publisher","unstructured":"Shaikh S, Lee EJ, Ahmad K, Ahmad SS, Lim JH, Choi I (2021) A comprehensive review and perspective on natural sources as dipeptidyl peptidase-4 inhibitors for management of diabetes. Pharmaceuticals (Basel)\u00a014:591. https:\/\/doi.org\/10.3390\/ph14060591.\u00a0PMID: 34203048; PMCID: PMC8235117","DOI":"10.3390\/ph14060591"},{"key":"3586_CR199","doi-asserted-by":"publisher","unstructured":"Gallwitz B (2019) Clinical use of DPP-4 inhibitors. Front endocrinol (Lausanne)\u00a010:389. https:\/\/doi.org\/10.3389\/fendo.2019.00389.\u00a0PMID: 31275246; PMCID: PMC6593043","DOI":"10.3389\/fendo.2019.00389"},{"key":"3586_CR200","doi-asserted-by":"publisher","unstructured":"Fukasawa KM, Fukasawa K, Sahara N, Harada M, Kondo Y, Nagatsu I (1981) Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands. J Histochem Cytochem\u00a029:337\u201343. https:\/\/doi.org\/10.1177\/29.3.6787113.\u00a0PMID: 6787113","DOI":"10.1177\/29.3.6787113"},{"key":"3586_CR201","doi-asserted-by":"publisher","unstructured":"Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y (2018) Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes metab Res Rev\u00a034. https:\/\/doi.org\/10.1002\/dmrr.2957.\u00a0PMID: 29054111","DOI":"10.1002\/dmrr.2957"},{"key":"3586_CR202","doi-asserted-by":"publisher","unstructured":"Ishii S, Nagai Y, Kato H, Fukuda H, Tanaka Y (2020) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on muscle mass and the muscle\/fat ratio in patients with type 2 diabetes. J Clin Med Res\u00a012:122\u2013126.\u00a0https:\/\/doi.org\/10.14740\/jocmr4078.\u00a0PMID: 32095182; PMCID: PMC7011940","DOI":"10.14740\/jocmr4078"},{"key":"3586_CR203","doi-asserted-by":"publisher","unstructured":"Baumeier C, Schl\u00fcter L, Saussenthaler S, Laeger T, R\u00f6diger M, Alaze SA, Fritsche L, H\u00e4ring HU, Stefan N, Fritsche A, Schwenk RW, Sch\u00fcrmann A (2017) Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol Metab\u00a06:1254\u20131263.\u00a0https:\/\/doi.org\/10.1016\/j.molmet.2017.07.016.\u00a0PMID: 29031724 PMCID: PMC5641684","DOI":"10.1016\/j.molmet.2017.07.016"},{"key":"3586_CR204","doi-asserted-by":"publisher","unstructured":"Itou M, Kawaguchi T, Taniguchi E, Sata M (2013) Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol\u00a019:2298\u2013306. https:\/\/doi.org\/10.3748\/wjg.v19.i15.2298.\u00a0PMID: 23613622; PMCID: PMC3631980","DOI":"10.3748\/wjg.v19.i15.2298"},{"key":"3586_CR205","doi-asserted-by":"publisher","unstructured":"Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R (2012) Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep\u00a05:729\u201333. https:\/\/doi.org\/10.3892\/mmr.2011.707.\u00a0PMID: 22179204","DOI":"10.3892\/mmr.2011.707"},{"key":"3586_CR206","doi-asserted-by":"publisher","unstructured":"Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R (2016) Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol\u00a065:369\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.021.\u00a0PMID: 27151177; PMCID: PMC5081213","DOI":"10.1016\/j.jhep.2016.04.021"},{"key":"3586_CR207","doi-asserted-by":"publisher","unstructured":"Hussain M, Majeed Babar MZ, Hussain MS, Akhtar L (2016) Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci\u00a032:1396\u20131401. https:\/\/doi.org\/10.12669\/pjms.326.11133. PMID: 28083033; PMCID: PMC5216289","DOI":"10.12669\/pjms.326.11133"},{"key":"3586_CR208","doi-asserted-by":"publisher","unstructured":"Deng XL, Ma R, Zhu HX, Zhu J (2017) Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol\u00a029:297\u2013301. https:\/\/doi.org\/10.1097\/MEG.0000000000000780.\u00a0PMID: 27832040","DOI":"10.1097\/MEG.0000000000000780"},{"key":"3586_CR209","doi-asserted-by":"publisher","unstructured":"Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol\u00a023:141\u2013150. https:\/\/doi.org\/10.3748\/wjg.v23.i1.141.\u00a0PMID: 28104990; PMCID: PMC5221278","DOI":"10.3748\/wjg.v23.i1.141"},{"key":"3586_CR210","doi-asserted-by":"publisher","unstructured":"Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N (2018) Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. Hepat Med 10:23\u201331. https:\/\/doi.org\/10.2147\/HMER.S158053.\u00a0PMID: 29740221; PMCID: PMC5931194","DOI":"10.2147\/HMER.S158053"},{"key":"3586_CR211","doi-asserted-by":"publisher","unstructured":"Komorizono Y, Hosoyamada K, Imamura N, Kajiya S, Hashiguchi Y, Ueyama N, Shinmaki H, Koriyama N, Tsukasa M, Kamada T (2021) Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: an analysis of the J-LINK study. Diabetes Obes Metab\u00a023:832\u2013837. https:\/\/doi.org\/10.1111\/dom.14263.\u00a0PMID: 33236464","DOI":"10.1111\/dom.14263"},{"key":"3586_CR212","doi-asserted-by":"publisher","unstructured":"Hattori S, Nomoto K, Suzuki T, Hayashi S (2021) Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis. Diabetol Metab Syndr\u00a013:28. https:\/\/doi.org\/10.1186\/s13098-021-00644-5. PMID: 33691757; PMCID: PMC7945344","DOI":"10.1186\/s13098-021-00644-5"},{"key":"3586_CR213","doi-asserted-by":"publisher","unstructured":"Yabiku K, Mutoh A, Miyagi K, Takasu N (2017) Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computed tomography and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease. Clin Ther 39:558\u2013566. https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.015.\u00a0PMID: 28185715","DOI":"10.1016\/j.clinthera.2017.01.015"},{"key":"3586_CR214","doi-asserted-by":"publisher","unstructured":"Dos Santos LR, Duarte ML, Peccin MS, Gagliardi ART, Melnik T (2021) Dipeptidyl peptidase IV inhibitors for nonalcoholic fatty liver disease - systematic review and metanalysis. Curr Diabetes Rev 17(5):e101120187811. https:\/\/doi.org\/10.2174\/1573399816999201110195634.\u00a0PMID: 33176658","DOI":"10.2174\/1573399816999201110195634"},{"key":"3586_CR215","doi-asserted-by":"publisher","unstructured":"Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, Kumar S, Siddiqi TJ, Usman MS (2021) Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis\u00a053:44\u201351. https:\/\/doi.org\/10.1016\/j.dld.2020.08.021.\u00a0PMID: 32912770","DOI":"10.1016\/j.dld.2020.08.021"},{"key":"3586_CR216","doi-asserted-by":"publisher","unstructured":"Zafar Y, Rashid AM, Siddiqi AK, Ellahi A, Ahmed A, Hussain HU, Ahmed F, Menezes RG, Siddiqi TJ, Maniya MT (2022) Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol\u00a046:101970. https:\/\/doi.org\/10.1016\/j.clinre.2022.101970.\u00a0PMID: 35659603","DOI":"10.1016\/j.clinre.2022.101970"},{"key":"3586_CR217","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol\u00a071:793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.\u00a0PMID: 31279902","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"3586_CR218","doi-asserted-by":"publisher","unstructured":"Jelenik T, Kaul K, S\u00e9quaris G, Fl\u00f6gel U, Phielix E, Kotzka J, Knebel B, Fahlbusch P, H\u00f6rbelt T, Lehr S, Reinbeck AL, M\u00fcller-Wieland D, Esposito I, Shulman GI, Szendroedi J, Roden M (2017) Mechanisms of insulin resistance in primary and secondary nonalcoholic fatty liver. Diabetes\u00a066:2241\u2013225. https:\/\/doi.org\/10.2337\/db16-1147.\u00a0PMID: 28490610 PMCID: PMC5521856","DOI":"10.2337\/db16-1147"},{"key":"3586_CR219","doi-asserted-by":"publisher","unstructured":"Finck BN (2018) Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis. Diabetes\u00a067:2485\u20132493. https:\/\/doi.org\/10.2337\/dbi18-0024.\u00a0PMID: 30459251; PMCID: PMC6245219","DOI":"10.2337\/dbi18-0024"},{"key":"3586_CR220","doi-asserted-by":"publisher","unstructured":"Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95\u201396. https:\/\/doi.org\/10.1016\/j.cmet.2007.12.009.\u00a0PMID: 18249166","DOI":"10.1016\/j.cmet.2007.12.009"},{"key":"3586_CR221","doi-asserted-by":"publisher","unstructured":"Manka PP, Kaya E, Canbay A, Syn WK (2021) A review of the epidemiology, pathophysiology, and efficacy of anti-diabetic drugs used in the treatment of nonalcoholic fatty liver disease. Dig Dis Sci 66:3676\u20133688. https:\/\/doi.org\/10.1007\/s10620-021-07206-9.\u00a0PMID: 34410573; PMCID: PMC8510897","DOI":"10.1007\/s10620-021-07206-9"},{"key":"3586_CR222","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0022-2275(20)38268-7","volume":"30","author":"N Dashti","year":"1989","unstructured":"Dashti N, Williams DL, Alaupovic P (1989) Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res 30:1365\u20131373 PMID: 2689548","journal-title":"J Lipid Res"},{"key":"3586_CR223","doi-asserted-by":"publisher","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S (2020) Insulin resistance drives hepatic de novo lipogenesis in non-alcoholic fatty liver disease. J Clin Invest 130:1453\u20131460. https:\/\/doi.org\/10.1172\/JCI134165.\u00a0PMID: 31805015; PMCID: PMC7269561","DOI":"10.1172\/JCI134165"},{"key":"3586_CR224","doi-asserted-by":"publisher","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-J\u00e4rvinen H, Fan JG, Gr\u00f8nb\u00e6k H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.\u00a0PMID: 32278004","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"3586_CR225","doi-asserted-by":"publisher","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne C, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer D, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot B, Korenjak M, Kowdley K, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell E, Roden M, Romero-G\u00f3mez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN, NAFLD Nomenclature consensus group (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology.\u00a0https:\/\/doi.org\/10.1097\/HEP.0000000000000520. Epub ahead of print.\u00a0PMID: 37363821","DOI":"10.1097\/HEP.0000000000000520"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03586-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:03:27Z","timestamp":1704870207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":225,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3586"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03586-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"1 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}